SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The stock is experiencing significant volatility driven by market skepticism regarding the upcoming REGAL clinical trial results, fueled by social media discourse that questions the company's statistical success models. Traders are debating whether the price decline represents a coordinated manipulation tactic to trigger stop losses or a genuine shift in sentiment following the exit of influential community voices.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The discussion on this symbol is heavily polarized, with significant community debate surrounding the potential impact of proposed economic stimulus checks and the administration's broader fiscal and foreign policies. Traders are expressing strong disagreement over the effectiveness of current leadership, with frequent arguments about government spending, inflation, and the geopolitical implications of ongoing conflicts.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is facing significant selling pressure and community criticism following the announcement of a new $1 billion at-the-market equity offering. Traders are expressing frustration over continued share dilution and insider selling, though some participants remain optimistic about the company's long-term potential in the nuclear energy sector.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Investors are closely watching upcoming settlement negotiations between Paramount and California's Attorney General regarding the Skydance-Warner Bros. Discovery merger. While community sentiment is heavily polarized, market participants are focused on the impact of potential structural concessions and the looming daily ticking fee that begins in October if the deal remains unclosed.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning shares are experiencing significant volatility following a second-quarter report where strong revenue growth and AI-driven optical demand were overshadowed by a conservative third-quarter guidance and manufacturing capacity concerns. Traders are debating whether the sharp pullback is an overreaction to short-term production constraints or the beginning of a larger correction in the AI infrastructure sector.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending following a favorable Ninth Circuit court ruling that allows states to regulate prediction market sports contracts, which investors view as a move to reduce competitive pressure from alternative betting platforms. Sentiment remains mixed, as traders debate the long-term impact of regulatory challenges versus seasonal growth potential heading into the NFL season.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is under pressure following a UBS downgrade to 'Sell' due to concerns over extended project timelines, a lack of firm customer commitments, and significant projected cash burn. While some traders view the resulting selloff as an overreaction and a buying opportunity, others express frustration with the company's lack of commercial progress and the potential for further dilution.

Alliance Entertainment Holding Corp. engages in the distribution of music, movies, and consumer electronics. It distributes its physical media, entertainment products, hardware, and accessories through an established multi-channel strategy. The company was founded in 1990 and is headquartered in Plantation, FL.

Alliance Entertainment Holding Corporation - Ordinary Shares - Class A

The community is primarily focused on the potential for a short squeeze, citing the company's low tradable float and high insider ownership as catalysts for volatility. Traders are debating the company's long-term value, specifically its pivot toward collectibles and physical media distribution, while others express frustration over the stock's recent price decline.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased attention as traders discuss bullish long-term infrastructure developments, such as the Chain acquisition and potential neobank integration, while competing voices characterize the price action as a recurring pump-and-dump scheme. The community remains divided between those accumulating for expected institutional adoption and those warning of potential dilution and lack of confirmed commercial partnerships.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is facing significant downward pressure following its Q2 2026 earnings report, which featured a revenue miss, a widened net loss, and a downward revision of full-year revenue guidance. The sell-off is further compounded by the announcement that the company's co-founders plan to depart by the end of 2026 to launch an independent mRNA-focused venture, leaving investors uncertain regarding near-term leadership stability and pipeline execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BMO Capital⬆️ $TSHA&#39;s PT to $14 (was $10),⬆️&#39;102&#39;s PoS in RTT to 55% (was 50%)—sees Tx pulling 70% market share—reit&#39;d Outperform and said: Durability Deepens With Updated REVEAL Data, Target to $14 on Differentiation 
$ACAD $NGNE AVXL UCBJY 
BMO Capital added—Derisked safety and further improvements in TSHA-102 efficacy increase our confidence in the asset as a leading Rett gene therapy. 
 
With TSHA-102 demonstrating additional increases in functional gains from prior updates, we increase our probability of success to 55% and increase our target price to $14/share. 
 
Long-term we expect TSHA-102 will be the leading Rett gene therapy, commanding 70% market share. 
 
Over enrollment in the pivotal REVEAL study reduces the statistical barrier for success, but given robust efficacy demonstrated at 6-months, we do not believe this is necessary.

Warren Collins

Citizens⬆️ $TSHA-$11,⬆️&#39;102&#39;s PoS and reiterated Market Outperform 
$ACAD $NGNE AVXL UCBJY 
Here&#39;s what Citizens said in its note: 
Taysha Gene Therapies updated REVEAL Part A data, with: 
1) an 83% response rate at six months that grew to a 100% response rate at 12 months — both significantly ahead of the 33% FDA bar; 
2) continued improvement with longer follow-up; 
3) data point to a high likelihood of passing the 33% response rate bar at the six-month interim readout in 1H27; 
4) continued excellent safety. 
 
We maintain our Market Outperform rating and increase our price target (DCF-derived) to $11 from $8 by increasing the TSHA-102 PoS to 66%, based on the strength of updated data.

StockTwits Web

Taysha Gene Therapies Inc

Acadia Pharmaceuticals Inc

Neurogene Inc

Quantumup

's PT to $14 (was $10),⬆️'102's PoS in RTT to 55% (was 50%)—sees Tx pulling 70% market share—reit'd Outperform and said: Durability Deepens With Updated REVEAL Data, Target to $14 on Differentiation 


 AVXL UCBJY 
BMO Capital added—Derisked safety and further improvements in TSHA-102 efficacy increase our confidence in the asset as a leading Rett gene therapy. 
 
With TSHA-102 demonstrating additional increases in functional gains from prior updates, we increase our probability of success to 55% and increase our target price to $14/share. 
 
Long-term we expect TSHA-102 will be the leading Rett gene therapy, commanding 70% market share. 
 
Over enrollment in the pivotal REVEAL study reduces the statistical barrier for success, but given robust efficacy demonstrated at 6-months, we do not believe this is necessary.